GNPDA1 Antibody

What is GNPDA1 and what biological functions does it serve?

GNPDA1 (Glucosamine-6-phosphate isomerase 1) is an enzyme that catalyzes the reversible conversion of alpha-D-glucosamine 6-phosphate (GlcN-6P) into beta-D-fructose 6-phosphate (Fru-6P) and ammonium ion. This represents a regulatory reaction step in de novo uridine diphosphate-N-acetyl-alpha-D-glucosamine (UDP-GlcNAc) biosynthesis via the hexosamine pathway . The enzyme plays a significant role in fine-tuning metabolic fluctuations of cytosolic UDP-GlcNAc and their effects on hyaluronan synthesis during tissue remodeling . Additionally, GNPDA1 appears to trigger calcium oscillations in mammalian eggs, which serve as essential triggers for egg activation and early embryonic development .

What are the key characteristics of commercially available GNPDA1 antibodies?

Current GNPDA1 antibodies share several common characteristics while offering different applications:

All documented antibodies are rabbit-derived polyclonals targeting different epitopes of human GNPDA1, with some showing cross-reactivity with rodent samples .

How do I select the appropriate GNPDA1 antibody for my experimental needs?

Selection of the optimal GNPDA1 antibody should be guided by:

• Experimental application: For Western blotting, antibodies A10820 (targeting amino acids 13-242) and 12312-1-AP have validated performance . For immunohistochemistry on paraffin sections, consider ab253023 or NBP2-97217FR .

• Species compatibility: While all antibodies work with human samples, 12312-1-AP has confirmed reactivity with mouse and rat samples . Cross-reactivity with other species (e.g., canine) may require validation through innovator programs offered by manufacturers .

• Labeling requirements: For fluorescence applications requiring direct visualization, consider pre-labeled options like NBP2-97217FR (DyLight 680, excitation 692nm/emission 712nm) .

• Epitope consideration: The immunogens used differ between antibodies, which may impact detection of specific GNPDA1 isoforms or truncated variants. A10820 targets amino acids 13-242, while ab253023 targets amino acids 100-200 .

What is the optimal protocol for using GNPDA1 antibodies in Western blotting?

For Western blotting with GNPDA1 antibodies, the following methodological approach is recommended:

• Sample preparation: Prepare tissue or cell lysates in RIPA buffer supplemented with protease inhibitors. The antibody has been successfully validated with human brain tissue, rat kidney tissue, K-562 cells, and HeLa cells .

• Protein loading and separation: Load 20-50 μg of total protein per lane. GNPDA1 has a molecular weight of approximately 32-33 kDa , so use an appropriate percentage gel (10-12% SDS-PAGE) for optimal resolution in this range.

• Transfer and blocking: Transfer to PVDF or nitrocellulose membrane using standard protocols. Block with 5% non-fat milk in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute primary antibody according to manufacturer recommendations (1:500-1:2000 for 12312-1-AP or 1-2 μg/ml for A10820) . Incubate overnight at 4°C with gentle agitation.

• Detection: Use appropriate HRP-conjugated secondary antibody and ECL detection system. GNPDA1 should be detected at approximately 33 kDa.

• Controls: Include positive controls (human brain tissue, K-562 cells, or HeLa cells) to validate antibody performance .

How should I optimize GNPDA1 antibody usage for immunohistochemistry?

For optimal immunohistochemical detection of GNPDA1 in paraffin-embedded tissues:

• Antigen retrieval: Two approaches have demonstrated success:

  • TE buffer pH 9.0 (recommended for 12312-1-AP)

  • Citrate buffer pH 6.0 (alternative method)

• Blocking and antibody dilution: Block with appropriate serum (typically 10% normal goat serum) for 30 minutes. Dilute antibody as recommended:

  • 1:20-1:200 for 12312-1-AP

  • Optimal dilution for NBP2-97217FR should be experimentally determined

• Incubation conditions: Incubate sections with primary antibody overnight at 4°C in a humidified chamber.

• Detection systems: For chromogenic detection, use appropriate HRP/AP secondary antibody systems. For fluorescence detection with unlabeled primary antibodies, use fluorophore-conjugated secondary antibodies, or use directly labeled antibodies like NBP2-97217FR (DyLight 680) .

• Tissue validation: Human pancreatic cancer tissue has been validated for GNPDA1 IHC detection .

How can I address cross-reactivity or specificity concerns with GNPDA1 antibodies?

Cross-reactivity assessment and specificity validation are crucial considerations:

• Knockout/knockdown validation: Several publications have utilized GNPDA1 antibodies in KD/KO systems, providing strong validation of specificity . Consider including GNPDA1 knockdown samples as negative controls.

• Epitope competition: For A10820, blocking peptides corresponding to the immunogen (amino acids 13-242) can be purchased to validate signal specificity through competition assays .

• Species cross-reactivity: While A10820 is validated for human samples, researchers interested in canine tissues may participate in innovator programs to validate cross-reactivity . The 12312-1-AP antibody demonstrates broader reactivity with human, mouse, and rat samples .

• Alternative detection methods: Validate findings using antibodies targeting different epitopes of GNPDA1 or employing alternative detection techniques (qPCR, mass spectrometry).

What considerations are important when investigating GNPDA1 in specialized tissues like testis?

When investigating GNPDA1 in reproductive tissues like testis:

• Tissue preparation: For frozen testis samples, optimal fixation protocols must be established experimentally. The A10820 antibody has been queried for use in human testis on frozen tissues, though validation data specifically for this tissue type was pending as of the documentation .

• Developmental expression patterns: GNPDA1 (also known as oscillin) has been implicated in egg activation and early embryonic development , suggesting potential developmental regulation in reproductive tissues.

• Specialized protocols: When working with testis-specific samples:

  • Consider using specialized extraction buffers that account for the high lipid content

  • For IHC applications, optimize antigen retrieval methods specifically for testicular tissue

  • Be aware of potential cross-reactivity with testis-specific proteins

• Validation approach: Researchers investigating novel applications (like GNPDA1 in testis) may benefit from manufacturer innovator programs that provide incentives for publishing validation data in new tissue types .

How can GNPDA1 antibodies be deployed in studying hexosamine pathway dysregulation in disease models?

GNPDA1 antibodies can provide valuable insights in disease research through:

• Metabolic disease studies: Since GNPDA1 regulates the reversible conversion between GlcN-6P and Fru-6P, it represents a key control point in glucose metabolism. Quantitative analysis of GNPDA1 expression using calibrated Western blotting can reveal alterations in hexosamine pathway activity in metabolic disorders.

• Cancer metabolism research: GNPDA1 antibodies have been validated in cancer cell lines (K-562, HeLa) and pancreatic cancer tissue , enabling studies of hexosamine pathway alterations in cancer metabolism.

• Multiplexing strategies: For comprehensive pathway analysis, GNPDA1 antibodies can be paired with antibodies targeting other hexosamine pathway components. The 12312-1-AP antibody's compatibility with mouse and rat samples facilitates translational research using rodent disease models .

• Subcellular localization studies: IHC-validated antibodies enable investigation of potential alterations in GNPDA1 subcellular distribution in disease states.

How can GNPDA1 antibodies contribute to studying calcium oscillation mechanisms in fertilization?

GNPDA1 (also known as oscillin) has been implicated in triggering calcium oscillations in mammalian eggs, which are essential for egg activation and early embryonic development . Researchers investigating fertilization mechanisms can utilize GNPDA1 antibodies to:

• Co-localization studies: Combine GNPDA1 antibodies with calcium signaling markers to examine spatial relationships during fertilization events.

• Temporal expression analysis: Track GNPDA1 expression patterns before, during, and after fertilization using Western blotting with A10820 or 12312-1-AP .

• Functional blocking experiments: Utilize GNPDA1 antibodies in fertilization systems to assess whether neutralizing the protein affects calcium oscillation patterns.

• Cross-species conservation: With 12312-1-AP showing reactivity across human, mouse and rat samples , comparative studies of GNPDA1's role in fertilization across mammalian species are feasible.

What methodological approaches can address contradictory findings when using different GNPDA1 antibody clones?

When faced with inconsistent results between different GNPDA1 antibody clones:

• Epitope mapping analysis: Since available antibodies target different epitopes (e.g., A10820 targets amino acids 13-242 while ab253023 targets amino acids 100-200) , discrepancies may result from detection of different GNPDA1 isoforms or post-translationally modified forms.

• Validation through orthogonal methods: Confirm protein expression through non-antibody methods such as mass spectrometry or mRNA analysis.

• Antibody cocktail approach: Consider using a combination of antibodies targeting different epitopes to achieve more comprehensive GNPDA1 detection.

• Standardized positive controls: Include consistent positive control samples (e.g., recombinant GNPDA1 protein, HeLa cells, or K-562 cells) across experiments with different antibodies to establish relative detection efficiencies.

• Systematic validation: Document and compare antibody performance across standardized protocols, considering variables such as fixation methods, antigen retrieval techniques, and detection systems.

What modifications are required when using GNPDA1 antibodies in fluorescence microscopy and multi-color imaging?

For successful fluorescence microscopy applications:

• Directly conjugated options: NBP2-97217FR with DyLight 680 (excitation 692nm/emission 712nm) provides a directly labeled option for far-red detection without requiring secondary antibodies .

• Multi-color imaging considerations: When designing multi-color panels:

  • Account for the spectral properties of DyLight 680 when selecting additional fluorophores

  • For unconjugated antibodies, select secondary antibodies with appropriate spectral properties

  • Consider antibody host species (all documented GNPDA1 antibodies are rabbit-derived) when designing panels with multiple primary antibodies

• Autofluorescence management: Particularly in tissues with high autofluorescence (like brain or liver), the far-red emission of NBP2-97217FR may help avoid native tissue autofluorescence, which typically occurs at shorter wavelengths .

• Live-cell compatibility: Current documentation does not indicate validation for live-cell applications, suggesting these antibodies are optimized for fixed-cell/tissue applications.

How should researchers approach GNPDA1 antibody-based studies in non-mammalian model systems?

When extending GNPDA1 research to non-mammalian models:

• Sequence homology assessment: GNPDA1 has evolutionarily conserved functions, with a Drosophila homolog (dNMDA1) showing 40% homology to human TMBIM1 and upregulation during aging and oxidative stress .

• Cross-reactivity validation: Though current antibodies are primarily validated for mammalian samples, researchers working with non-mammalian models should:

  • Perform Western blot validation using recombinant GNPDA1 from the species of interest

  • Include appropriate positive and negative controls from the target species

  • Consider epitope sequence alignment to predict potential cross-reactivity

• Alternative approaches: For species with limited antibody cross-reactivity, consider:

  • Generating species-specific antibodies using conserved epitopes

  • Employing tagged GNPDA1 expression constructs detectable with tag-specific antibodies

  • Utilizing genomic/proteomic approaches that don't rely on antibody detection